• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Guard Therapeutics presents the Nomination Committee for 2026

Guard Therapeutics
Download the release

Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.

According to previous AGM resolutions, a Nomination Committee shall be appointed for the election and remuneration of the Board of Directors. The Nomination Committee shall consist of four members – one representative of each of the three largest shareholders who have accepted the assignment and the Chairman of the Board.

The Nomination Committee has now been appointed and consists of the following members:

  • Jan Ståhlberg, representing own holdings
  • Peter Wolpert, representing Stiftelsen Industrifonden
  • Linda Karlsson Engdahl, representing Räfsab AB
  • Johan Bygge, Chairman of the Board

Prior to the 2026 Annual General Meeting, the Nomination Committee shall submit proposals for; chairman of the annual general meeting, number of board members elected by the AGM, chairman and other members of the board elected by the AGM, fees and other remuneration to each of the board members elected by the AGM and to members of the board's committees (where applicable), number of auditors, auditors, fees to auditors and election of the nomination committee (alternatively, a decision on principles for the appointment of the Nomination Committee, as well as a decision on instructions for the Nomination Committee in cases where the Nomination Committee considers that the applicable principles and instructions should be updated). The Nomination Committee's proposals will be presented in the notice convening the Annual General Meeting 2026.

For further information, please contact:


Johan Bygge, Chairman of the Board
Telephone: +46 8 670 65 51
E-mail: info@guardtherapeutics.com

About Guard Therapeutics


Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with a large unmet medical need, focusing on different forms of kidney disease. The company’s candidate drugs are based on the endogenous protein alpha-1-microglobulin. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm (ticker: GUARD).

Certified Adviser is Redeye AB, Certified Adviser - Redeye.

Attachments


Guard Therapeutics presents the Nomination Committee for 2026